biostudies-literatureUnknown106(5)Sasako TMinistry of Health, Labour and Welfare of JapanJapan Agency for Medical Research and DevelopmentManpei Suzuki Diabetes FoundationJapan Diabetes Society<h4>Aims</h4>To evaluate the effects of an intensified multifactorial intervention and patient characteristics on the incidence of fractures comorbid with type 2 diabetes.<h4>Methods</h4>Fracture events were identified and analyzed among adverse events reported in the J-DOIT3 study, a multicenter, open-label, randomized, parallel-group trial that was conducted in Japan, in which patients with type 2 diabetes were randomly assigned to receive conventional therapy for glucose, blood pressure, and lipids (targets: HbA1c < 6.9%, blood pressure <130/80 mm Hg, LDL-cholesterol <120mg/dL) or intensive therapy (HbA1c < 6.2%, blood pressure <120/75 mm Hg, LDL-cholesterol <80mg/dL) (ClinicalTrials.gov registration no. NCT00300976).<h4>Results</h4>The cumulative incidence of fractures did not differ bThe Journal of clinical endocrinology and metabolisme2116-e2128https://www.ebi.ac.uk/biostudies/studies/S-EPMC8063245biostudies-literatureEffect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study.PMC8063245Sasako TOkazaki YUeki KMiyake KOhashi YKadowaki TTakeuchi YNoda MfalseEffect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study.<h4>Aims</h4>To evaluate the effects of an intensified multifactorial intervention and patient characteristics on the incidence of fractures comorbid with type 2 diabetes.<h4>Methods</h4>Fracture events were identified and analyzed among adverse events reported in the J-DOIT3 study, a multicenter, open-label, randomized, parallel-group trial that was conducted in Japan, in which patients with type 2 diabetes were randomly assigned to receive conventional therapy for glucose, blood pressure, and lipids (targets: HbA1c < 6.9%, blood pressure <130/80 mm Hg, LDL-cholesterol <120mg/dL) or intensive therapy (HbA1c < 6.2%, blood pressure <120/75 mm Hg, LDL-cholesterol <80mg/dL) (ClinicalTrials.gov registration no. NCT00300976).<h4>Results</h4>The cumulative incidence of fractures did not differ b2021-01-01T00:00:00Z2021 Apr2025-04-03T21:04:15.586Z2022-02-11T14:14:37.959ZS-EPMC80632453349108710.1210/clinem/dgab013